Abstract
Incretin-based therapy leads to glycemic control in a glucose-dependent manner with a low risk of hypoglycemia, making it appealing for use in the hospital. The aim of this systematic review was to assess the benefits of incretin-based therapy in patients with type 2 diabetes hospitalized outside of the intensive care unit. We searched for studies published up to August 2021 in the PubMed and Scopus databases. Clinical trials comparing incretin-based therapy (alone or in combination with insulin) versus an insulin regimen were selected. The results of the included studies showed that incretin-based therapy showed mean blood glucose values, a percentage of records within the therapeutic target, and a percentage of treatment failure similar to insulin management, particularly in patients with mild to moderate hyperglycemia. Furthermore, incretin-based treatment was associated with a lower total insulin dose and a lower incidence of hypoglycemia. In conclusion, incretin-based therapy achieved glycemic control similar to insulin treatment in patients with type 2 diabetes hospitalized outside the intensive care unit and has the advantages of reducing the insulin requirement and a lower risk of hypoglycemia.
Translated title of the contribution | Incretin-based therapy for glycemic control of hospitalized patients with type 2 diabetes: a systematic review |
---|---|
Original language | English |
Pages (from-to) | 180-189 |
Number of pages | 10 |
Journal | Revista Clinica Espanola |
Volume | 222 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- Antidiabetics
- Diabetes
- Incretins
- Inpatient
- Insulin